title: Antileukemia T-cell responses in CLL - We don't need no aberration.
abstract: Effective antigen-specific cancer immunotherapy requires exact knowledge of tumor-associated epitopes that can act as rejection antigens. Although the current paradigm views mutation-derived neoantigens as the most promising targets, we have recently demonstrated that leukemia-specific T-cell responses associated with survival benefit in CLL patients target a panel of non-mutated tumor-associated antigens.
authors.affiliation: Institute for Cell Biology; Department of Immunology; University of Tübingen; Tübingen , Germany.
authors.forename: Daniel J
authors.initials: DJ
authors.lastname: Kowalewski
authors.affiliation: Institute for Cell Biology; Department of Immunology; University of Tübingen; Tübingen , Germany ; German Cancer Consortium (DKTK), DKFZ Partner Site ; Tübingen, Germany.
authors.forename: Stefan
authors.initials: S
authors.lastname: Stevanovic
authors.affiliation: Institute for Cell Biology; Department of Immunology; University of Tübingen; Tübingen , Germany ; German Cancer Consortium (DKTK), DKFZ Partner Site ; Tübingen, Germany.
authors.forename: Hans-Georg
authors.initials: HG
authors.lastname: Rammensee
authors.affiliation: Department of Hematology and Oncology; University of Tübingen ; Tübingen, Germany.
authors.forename: Juliane S
authors.initials: JS
authors.lastname: Stickel
keywords: cancer immunotherapy; chronic lymphocytic leukemia; neoantigen; tumor-associated antigen